Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus on EGFR-Targeted Therapy

Monday
5 December 2016
17.45 – 19.15

Hall C7
Messe Wien Exhibition & Congress Center
Messeplatz 1
Vienna, Austria

This program was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.

This educational activity is supported by Boehringer Ingelheim Pharma GmbH & Co. KG.
Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus on EGFR-Targeted Therapy

Monday, 5 December 2016
17.45–19.15

Hall C7
Messe Wien Exhibition & Congress Center

Chair
Martin Schuler, MD
German Cancer Center
University Hospital Essen
Essen, Germany

Faculty
Barbara Melosky, MD, FRCPC
British Columbia Cancer Agency
Vancouver, British Columbia, Canada

Marianne Nicolson, MD, FRCP
Aberdeen Royal Infirmary
Aberdeen, Scotland

Keunchil Park, MD, PhD
Samsung Medical Center
Sungkyunkwan University
Seoul, South Korea

Register online: www.prIMEoncology.org/egfr-vienna

Agenda
17.45 Welcome and warm-up quiz
Martin Schuler, MD

17.50 Key decision points for personalized patient care of advanced non-small cell lung cancer (NSCLC)
Martin Schuler, MD

18.00 Managing EGFR–mutant adenocarcinoma: What is the optimal first-line approach?
Barbara Melosky, MD, FRCPC

18.20 Tackling acquired resistance to EGFR–targeted therapy: Evaluating current and emerging treatment strategies
Keunchil Park, MD, PhD

18.40 Contemporary management of squamous cell carcinoma: What is the role of EGFR–targeted therapy in the era of immunotherapy?
Marianne Nicolson, MD, FRCP

18.55 Quiz questions revisited and questions from the audience
Martin Schuler, MD, and Faculty Panel

19.10 prIME Points™
Martin Schuler, MD

19.15 Adjourn

Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Sunshine Act and EFPIA Disclosure Code
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.